• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[卵巢癌中肿瘤标志物与临床症状的关系]

[Relationship between tumor markers and clinical symptoms in ovarian cancer].

作者信息

Yakushiji M, Nishimura H

机构信息

Department of Obstetrics & Gynecology, Kurume University School of Medicine.

出版信息

Rinsho Byori. 1992 Apr;40(4):354-8.

PMID:1593760
Abstract

To assess their usefulness in the prediction of tumor recurrence, we retrospectively examined the accuracy of preoperative diagnosis of ovarian cancer based on tumor markers on 279 patients with benign and malignant ovarian tumors treated at our department. Of the tumor markers examined, CA125 had the highest diagnostic accuracy, suggesting that it is the most useful marker in the diagnosis of ovarian cancer. TPA and IAP were found to be relatively useful, the tumor markers recently identified, CA72-4 had a high true positive rate. We examined the factors affecting the cut-off value for CA125 in healthy volunteers and determined the corrected cut-off value. Using this value, we assessed the usefulness of CA125 in distinguishing between benign and malignant tumors and in predicting tumor recurrence. Factors found to affect the serum CA125 level included pregnancy, menstrual cycle, dysmenorrhea, menopause, and blood type. Using our equation for women over 40 years of age, we obtained a specific cut-off level of 16 U/ml for postmenopausal women, which was found to more accurately distinguish between ovarian tumors in this age group than did the conventional cut-off level of 35 U/ml, which has been used for all age groups. Furthermore, the specific cut-off level predicted tumor recurrence about 2 months earlier than did the conventional cut-off value. In tumor recurrence, CA125 had risen gradually but was within the normal range. Tumor recurrence was observed in all patients who had shown continuous three-stage elevation of CA125 within the normal range.

摘要

为评估肿瘤标志物在预测肿瘤复发中的作用,我们回顾性研究了我院收治的279例卵巢良恶性肿瘤患者基于肿瘤标志物的卵巢癌术前诊断准确性。在所检测的肿瘤标志物中,CA125诊断准确性最高,提示其为卵巢癌诊断中最有用的标志物。TPA和IAP相对有用,新发现的肿瘤标志物CA72-4真阳性率较高。我们研究了影响健康志愿者CA125临界值的因素并确定了校正后的临界值。利用该值,我们评估了CA125在鉴别良恶性肿瘤及预测肿瘤复发中的作用。发现影响血清CA125水平的因素包括妊娠、月经周期、痛经、绝经和血型。对于40岁以上女性,使用我们的公式得出绝经后女性的特定临界值为16 U/ml,发现该值比用于所有年龄组的传统临界值35 U/ml能更准确地区分该年龄组的卵巢肿瘤。此外,特定临界值比传统临界值能提前约2个月预测肿瘤复发。在肿瘤复发时,CA125逐渐升高但在正常范围内。在所有CA125在正常范围内连续三期升高的患者中均观察到肿瘤复发。

相似文献

1
[Relationship between tumor markers and clinical symptoms in ovarian cancer].[卵巢癌中肿瘤标志物与临床症状的关系]
Rinsho Byori. 1992 Apr;40(4):354-8.
2
[Diagnosis of ovarian tumor by measuring tumor markers].[通过测量肿瘤标志物诊断卵巢肿瘤]
Rinsho Byori. 1992 Feb;40(2):133-8.
3
[Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Gan To Kagaku Ryoho. 1993 Feb;20(2):279-85.
4
[Clinical value of a new serum tumor marker CA602 in ovarian cancers].新型血清肿瘤标志物CA602在卵巢癌中的临床价值
Nihon Gan Chiryo Gakkai Shi. 1990 Jul 20;25(7):1454-60.
5
[Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Gan To Kagaku Ryoho. 1994 May;21(6):823-32.
6
[Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].血清CA19-9、CA125和CP2在黏液性卵巢肿瘤中的临床价值:273例患者的回顾性研究
Zhonghua Fu Chan Ke Za Zhi. 2008 Jan;43(1):5-8.
7
IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.免疫微粒酶促放大测定法(IMMULITE OM-MA检测):一种用于诊断良性和恶性卵巢肿瘤患者的有用工具。
Anticancer Res. 1999 Jul-Aug;19(4A):2535-6.
8
Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.上皮性卵巢癌患者的肿瘤相关胰蛋白酶抑制剂(TATI)和癌抗原125(CA125)
Anticancer Res. 1995 Nov-Dec;15(6B):2727-30.
9
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.可溶性表皮生长因子受体(sEGFR)[校正后]和癌抗原125(CA125)作为上皮性卵巢癌的筛查和诊断检测。
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. doi: 10.1158/1055-9965.EPI-04-0423.
10
Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.术前血浆骨桥蛋白水平作为一种生物标志物,在预测卵巢癌方面可作为糖类抗原125的补充。
J Obstet Gynaecol Res. 2006 Jun;32(3):309-14. doi: 10.1111/j.1447-0756.2006.00403.x.